Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03818087 | Elevate! : An Elderly Breast Cancer Cohort Study | active not recruiting | — | 253 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04691297 | Digitally Enhanced Smoking Cessation for High Risk Smokers | active not recruiting | N/A | 153 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04379414 |
| YES Study - Newly Diagnosed/Metastatic Intervention(YES) |
| active not recruiting |
| N/A |
| 400 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Dec 9, 2025 |
| clinicaltrials |
| NCT05168930 | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT01754025 | INHERIT EGFR - Studying Germline EGFR Mutations(INHERIT) | active not recruiting | — | 121 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01516190 | The Preoperative Health & Body Study(PreHab) | active not recruiting | N/A | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03657628 | Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue | active not recruiting | N/A | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06322888 | Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D) | recruiting | N/A | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT)(MARGOT) | active not recruiting | Phase 2 | 174 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04115254 | Stereotactic Magnetic Resonance Guided Radiation Therapy | recruiting | N/A | 397 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT00264602 | Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer | active not recruiting | Phase 1 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06677190 | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | recruiting | Phase 1 / Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT01191697 | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT03747419 | Avelumab and Radiation in Muscle-Invasive Bladder Cancer | terminated | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05265429 | Biology of Young Lung Cancer Study: The YOUNG LUNG Study | recruiting | — | 500 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04826393 | ASP8374 + Cemiplimab in Recurrent Glioma | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT03609177 | Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly(ACP-PEACE) | completed | N/A | 13,800 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT00136435 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 2 | Oct 20, 2025 | clinicaltrials |
| NCT04678401 | IS-free Treg HaploHCT | recruiting | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06507930 | The COMPASSION Study | recruiting | N/A | 200 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT02489617 | The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy | completed | N/A | 246 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06664151 | A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision | recruiting | Early Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT01982448 | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | completed | Phase 2 | 147 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05509439 | Home Transfusion for HEME | completed | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05565638 | PROFAST Intervention in Precursor Multiple Myeloma(PROFAST) | completed | N/A | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04883671 | Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial | recruiting | N/A | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06487247 | HEME Home Transfusion Program | recruiting | N/A | 700 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT01753089 | Dendritic Cell Activating Scaffold in Melanoma | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT00165425 | Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation | active not recruiting | N/A | 210 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT02880319 | Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone | active not recruiting | Phase 2 | 150 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT03022032 | The HOPE Trial and the SMART Study | completed | N/A | 102 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT03899805 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | completed | Phase 2 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05629065 | Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)((PATH-SIC)) | active not recruiting | N/A | 800 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT03850912 | Symptom Management Implementation of Patient Reported Outcomes in Oncology(SIMPRO) | completed | N/A | 42,808 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT02916771 | Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04118036 | Abemaciclib + Pembrolizumab In Glioblastoma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04627064 | ABEMA Alone or in COMBO With MK-6482 | completed | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03246958 | Nivolumab Plus Ipilimumab in Thyroid Cancer | completed | Phase 2 | 53 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03341936 | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN | active not recruiting | Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04024878 | NeoVax With Nivolumab in Patients With Ovarian Cancer | active not recruiting | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT02903368 | Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy | completed | Phase 2 | 118 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT00476190 | ALL Adult Consortium Trial: Adult ALL Trial | completed | Phase 2 | 112 | Dana-Farber Cancer InstituteOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT04406272 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | terminated | Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05866887 | Insomnia Prevention in Children With Acute Lymphoblastic Leukemia | completed | N/A | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | terminated | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT03294694 | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | terminated | Phase 1 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04081259 | LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy | completed | Phase 1 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT03170648 | Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study | completed | N/A | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT02040857 | Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer | completed | Phase 2 | 162 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials